# Relates to requiring a referenced rate for prescription drug

**Bill ID:** A9086
**Session:** 2024
**Sponsor:** Sarahana Shrestha
**Status:** In Assembly Committee
**PDF:** [A9086 PDF](https://legislation.nysenate.gov/pdf/bills/2024/A9086)

## Summary

Relates to reducing the cost of prescription drugs by establishing maximum wholesale drug prices that are the same as the prices in Canada.

---

## Full Text

S T A T E  O F  N E W  Y O R K
 ________________________________________________________________________
 
  9086
 
  I N  A S S E M B L Y
 
  February 6, 2024
  ___________
 
 Introduced by M. of A. SHRESTHA -- read once and referred to the Commit-
  tee on Insurance
 
 AN ACT to amend the insurance law, in relation to requiring a referenced
  rate for prescription drugs
 
  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
  Section 1. The insurance law is amended by adding a new section  111-b
 to read as follows:
  ยง  111-B. PILOT PROGRAM ON REFERENCED RATE FOR PRESCRIPTION DRUGS. (A)
 A PILOT PROGRAM IS HEREBY CREATED TO STUDY THE POSSIBILITY  OF  CONTROL-
 LING EXCESSIVE AND UNCONSCIONABLE PRICES FOR PRESCRIPTION DRUGS.
  (B)  DEFINITIONS.  AS  USED IN THIS SECTION, THE FOLLOWING TERMS SHALL
 HAVE THE FOLLOWING MEANINGS:
  (1) "PRESCRIPTION DRUG" SHALL HAVE THE SAME MEANING AS IN  SUBDIVISION
 SEVEN OF SECTION SIXTY-EIGHT HUNDRED TWO OF THE EDUCATION LAW, FOR WHICH
 A  PRESCRIPTION  IS  REQUIRED  UNDER THE FEDERAL FOOD, DRUG AND COSMETIC
 ACT. ANY DRUG THAT DOES NOT REQUIRE A PRESCRIPTION UNDER SUCH  ACT,  BUT
 WHICH  WOULD  OTHERWISE  MEET  THE  CRITERIA  UNDER ARTICLE TWO-A OF THE
 PUBLIC HEALTH LAW FOR INCLUSION ON THE PREFERRED DRUG LIST MAY BE  ADDED
 TO THE PREFERRED DRUG LIST UNDER ARTICLE TWO-A OF THE PUBLIC HEALTH LAW;
 AND,  IF  SO INCLUDED, SHALL BE CONSIDERED TO BE A PRESCRIPTION DRUG FOR
 PURPOSES OF THIS  SECTION;  PROVIDED  THAT  IT  SHALL  BE  ELIGIBLE  FOR
 REIMBURSEMENT  UNDER  A STATE PUBLIC HEALTH PLAN WHEN ORDERED BY A PRES-
 CRIBER AUTHORIZED TO PRESCRIBE UNDER THE STATE PUBLIC  HEALTH  PLAN  AND
 THE PRESCRIPTION IS SUBJECT TO THE APPLICABLE PROVISIONS OF THIS SECTION
 AND  PARAGRAPH  (A)  OF SUBDIVISION FOUR OF SECTION THREE HUNDRED SIXTY-
 FIVE-A OF THE SOCIAL SERVICES LAW.
  (2) "WHOLESALE ACQUISITION  COST"  SHALL  HAVE  THE  SAME  MEANING  AS
 DEFINED IN 42 U.S.C. ยง 1395W-3A.
  (3)  "STATE  ENTITY"  MEANS  ANY  AGENCY  OF THE STATE GOVERNMENT THAT
 PURCHASES PRESCRIPTION DRUGS ON BEHALF OF THE STATE FOR A  PERSON  WHOSE
 HEALTH  CARE  IS  PAID  FOR  BY  THE STATE, INCLUDING ANY AGENT, VENDOR,
 FISCAL AGENT, CONTRACTOR, OR OTHER PARTY ACTING ON BEHALF OF THE  STATE.
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
  [ ] is old law to be omitted.
  LBD02470-03-4
 A. 9086  2
 
 "STATE  ENTITY"  SHALL NOT INCLUDE THE MEDICAL ASSISTANCE PROGRAM ESTAB-
 LISHED PURSUANT TO 42 U.S.C. ยง 1396 ET SEQ.
  (4)  "HEALTH PLAN" SHALL HAVE THE SAME MEANING AS DEFINED IN PARAGRAPH
 (A) OF SUBDIVISION ONE OF SECTION TWO HUNDRED  EIGHTY-A  OF  THE  PUBLIC
 HEALTH LAW.
  (5) "REFERENCED RATE" MEANS THE MAXIMUM RATE ESTABLISHED BY THE SUPER-
 INTENDENT  UTILIZING  THE  WHOLESALE  ACQUISITION COST AND OTHER PRICING
 DATA DESCRIBED IN SUBSECTION (E) OF THIS SECTION.
  (6) "REFERENCED DRUGS" MEANS ANY PRESCRIPTION DRUG SUBJECT TO A REFER-
 ENCED RATE.
  (C) PAYMENT IN EXCESS OF REFERENCED RATE PROHIBITED. (1) IT SHALL BE A
 VIOLATION OF THIS SECTION FOR A STATE ENTITY OR HEALTH PLAN TO  PURCHASE
 THE  REFERENCED  DRUGS  SUBJECT TO THIS PILOT PROGRAM AND WHICH SHALL BE
 DISPENSED OR DELIVERED TO A CONSUMER IN THE STATE, WHETHER  DIRECTLY  OR
 THROUGH  A  DISTRIBUTOR,  FOR  A COST HIGHER THAN THE REFERENCED RATE AS
 DETERMINED PURSUANT TO PARAGRAPH TWO OF SUBSECTION (E) OF THIS SECTION.
  (2) IT SHALL BE A VIOLATION OF THIS SECTION FOR ANY PHARMACY  LICENSED
 IN  THIS STATE TO PURCHASE FOR SALE OR DISTRIBUTION REFERENCED DRUGS FOR
 A COST THAT EXCEEDS THE REFERENCED RATE TO A PERSON WHOSE HEALTH CARE IS
 PROVIDED BY A STATE ENTITY OR HEALTH PLAN.
  (D) COSTLY PRESCRIPTION DRUGS. AS PART  OF  THIS  PILOT  PROGRAM,  THE
 DIRECTOR  OF  THE  EMPLOYEE  BENEFITS  DIVISION WITHIN THE DEPARTMENT OF
 CIVIL SERVICE SHALL IDENTIFY THE FIVE  MOST  COSTLY  PRESCRIPTION  DRUGS
 BASED UPON NET PRICE TIMES UTILIZATION.
  (E)  REFERENCED DRUGS DETERMINED. (1) BEGINNING WITH CALENDAR YEAR TWO
 THOUSAND TWENTY-FIVE, NO LATER THAN JUNE THIRTIETH, THE DIRECTOR OF  THE
 EMPLOYEE  BENEFITS DIVISION WITHIN THE DEPARTMENT OF CIVIL SERVICE SHALL
 TRANSMIT TO THE SUPERINTENDENT THE LIST OF PRESCRIPTION DRUGS REFERENCED
 IN SUBSECTION (D) OF THIS SECTION. FOR EACH OF THESE PRESCRIPTION DRUGS,
 SUCH DIRECTOR SHALL ALSO PROVIDE THE TOTAL NET SPEND ON  EACH  OF  THOSE
 PRESCRIPTION DRUGS FOR THE PREVIOUS CALENDAR YEAR.
  (2)  UTILIZING  THE  INFORMATION  DESCRIBED  IN  PARAGRAPH ONE OF THIS
 SUBSECTION, NO LATER THAN NOVEMBER FIRST, TWO THOUSAND TWENTY-FIVE,  THE
 SUPERINTENDENT  SHALL  CREATE  AND  PUBLISH  A  LIST ON THE DEPARTMENT'S
 WEBSITE OF SUCH DRUGS THAT SHALL BE SUBJECT TO THE REFERENCED RATE.
  (3) THE SUPERINTENDENT SHALL DETERMINE THE REFERENCED RATE BY  COMPAR-
 ING THE WHOLESALE ACQUISITION COST TO THE COST FROM ALL OF THE FOLLOWING
 SOURCES:
  (A)  ONTARIO  MINISTRY  OF HEALTH AND LONG TERM CARE AND MOST RECENTLY
 PUBLISHED ON THE ONTARIO DRUG BENEFIT FORMULARY;
  (B) REGIE DE L'ASSURANCE MALADIE DU QUEBEC AND MOST RECENTLY PUBLISHED
 ON THE QUEBEC PUBLIC DRUG PROGRAMS LIST OF MEDICATIONS;
  (C) BRITISH COLUMBIA MINISTRY OF HEALTH AND MOST RECENTLY PUBLISHED ON
 THE BC PHARMACARE FORMULARY; AND
  (D) ALBERTA MINISTRY OF HEALTH AND  MOST  RECENTLY  PUBLISHED  ON  THE
 ALBERTA DRUG BENEFIT LIST.
  (4) THE REFERENCED RATE FOR EACH PRESCRIPTION DRUG SHALL BE CALCULATED
 AS  THE  LOWEST COST AMONG THOSE RESOURCES AND THE WHOLESALE ACQUISITION
 COST. IF A SPECIFIC REFERENCED DRUG IS NOT INCLUDED WITHIN THE RESOURCES
 DESCRIBED IN PARAGRAPH THREE OF THIS SUBSECTION, THEN, FOR  THE  PURPOSE
 OF  DETERMINING  THE  REFERENCED  RATE FOR THAT DRUG, THE SUPERINTENDENT
 SHALL UTILIZE THE CEILING PRICE FOR DRUGS AS REPORTED BY THE  GOVERNMENT
 OF CANADA PATENTED MEDICINE PRICES REVIEW BOARD.
  (5)  THE  SUPERINTENDENT SHALL CALCULATE THE SAVINGS THAT ARE EXPECTED
 TO BE ACHIEVED BY SUBJECTING PRESCRIPTION DRUGS TO THE  REFERENCED  RATE
 FOR ONE PLAN YEAR. IN MAKING THIS DETERMINATION THE SUPERINTENDENT SHALL
 A. 9086  3
 
 CONSULT  WITH  THE DIRECTOR OF THE EMPLOYEE BENEFITS DIVISION WITHIN THE
 DEPARTMENT OF CIVIL SERVICE AND THE DRUG ACCOUNTABILITY BOARD.
  (6)  THE SUPERINTENDENT SHALL PROMULGATE SUCH RULES AND REGULATIONS AS
 MAY BE NECESSARY TO CARRY OUT THIS PILOT PROGRAM.
  (F) APPLICATION OF SAVINGS. (1) ANY SAVINGS GENERATED BECAUSE  OF  THE
 REQUIREMENTS PURSUANT TO SUBSECTION (C) OF THIS SECTION SHALL BE USED TO
 REDUCE  COSTS TO CONSUMERS. ANY STATE ENTITY OR HEALTH PLAN SHALL CALCU-
 LATE SUCH SAVINGS AND UTILIZE SUCH SAVINGS DIRECTLY TO REDUCE COSTS  FOR
 ITS MEMBERS OR INSUREDS.
  (2)  NO  LATER THAN APRIL FIRST OF THE CALENDAR YEAR AFTER THE CONCLU-
 SION OF THE PILOT PROGRAM, EACH STATE ENTITY OR HEALTH PLAN  SUBJECT  TO
 THIS  SECTION SHALL SUBMIT TO THE SUPERINTENDENT A REPORT DESCRIBING THE
 SAVINGS ACHIEVED FOR EACH REFERENCED DRUG AND  HOW  THOSE  SAVINGS  WERE
 USED  TO  ACHIEVE  THE REQUIREMENTS OF PARAGRAPH ONE OF THIS SUBSECTION.
 THE SUPERINTENDENT SHALL SUBMIT A REPORT OF THE SAVINGS, IF ANY, OF  THE
 PILOT  PROGRAM  CONDUCTED PURSUANT TO THIS SECTION, TO THE GOVERNOR, THE
 TEMPORARY PRESIDENT OF THE SENATE, THE SPEAKER OF THE ASSEMBLY, AND  THE
 MINORITY  LEADERS  OF  THE SENATE AND ASSEMBLY NO LATER THAN ONE HUNDRED
 EIGHTY DAYS FOLLOWING THE CONCLUSION OF THE PLAN YEAR  SUBJECT  TO  THIS
 SECTION.  THE REPORT SHALL ALSO INCLUDE RECOMMENDATIONS ON THE FEASIBIL-
 ITY OF EXPANDING THIS PROGRAM TO OTHER PRESCRIPTION  DRUGS,  RECOMMENDA-
 TIONS  ON IMPROVEMENTS TO THE PROGRAM, AND ANY OTHER FINDINGS, RECOMMEN-
 DATIONS, OR CONCLUSIONS THE SUPERINTENDENT DEEMS NECESSARY TO UNDERSTAND
 THE BROADER EFFECTS OF THIS PILOT PROGRAM.
  (G) WITHDRAWAL OF REFERENCED DRUGS FOR SALE; PROHIBITED. (1) IT  SHALL
 BE  A VIOLATION OF THIS SECTION FOR ANY MANUFACTURER OR DISTRIBUTOR OF A
 REFERENCED DRUG TO WITHDRAW THAT DRUG FROM SALE OR  DISTRIBUTION  WITHIN
 THIS STATE FOR THE PURPOSE OF AVOIDING THE IMPACT OF THIS PILOT PROGRAM.
  (2)  ANY  MANUFACTURER THAT INTENDS TO WITHDRAW A REFERENCED DRUG FROM
 SALE OR DISTRIBUTION FROM WITHIN THE STATE SHALL  PROVIDE  A  NOTICE  OF
 WITHDRAWAL  IN WRITING TO THE SUPERINTENDENT AND TO THE ATTORNEY GENERAL
 NOT LESS THAN ONE HUNDRED EIGHTY DAYS PRIOR TO SUCH WITHDRAWAL.
  (3) THE SUPERINTENDENT SHALL ASSESS A PENALTY ON ANY  MANUFACTURER  OR
 DISTRIBUTOR THAT THEY DETERMINE TO HAVE WITHDRAWN A REFERENCED DRUG FROM
 DISTRIBUTION  OR  SALE IN THE STATE IN VIOLATION OF PARAGRAPH ONE OR TWO
 OF THIS SUBSECTION. WITH RESPECT TO EACH REFERENCED DRUG FOR  WHICH  THE
 SUPERINTENDENT  HAS DETERMINED THE MANUFACTURER OR DISTRIBUTOR HAS WITH-
 DRAWN FROM THE MARKET, THE PENALTY SHALL BE EQUAL TO:
  (A) FIVE HUNDRED THOUSAND DOLLARS; OR
  (B) THE AMOUNT OF ANNUAL SAVINGS DETERMINED BY THE  SUPERINTENDENT  AS
 DESCRIBED IN PARAGRAPH FIVE OF THIS SUBSECTION, WHICHEVER IS GREATER.
  (4)  IT  SHALL  BE A VIOLATION OF THIS SECTION FOR ANY MANUFACTURER OR
 DISTRIBUTOR OF A REFERENCED DRUG TO REFUSE TO NEGOTIATE  IN  GOOD  FAITH
 WITH  ANY  PAYOR  OR SELLER OF PRESCRIPTION DRUGS A PRICE THAT IS WITHIN
 THE REFERENCED RATE AS DETERMINED IN PARAGRAPH TWO OF SUBSECTION (E)  OF
 THIS SECTION.
  (5)  THE  SUPERINTENDENT SHALL ASSESS A PENALTY ON ANY MANUFACTURER OR
 DISTRIBUTOR THAT IT DETERMINES HAS FAILED TO NEGOTIATE IN GOOD FAITH  IN
 VIOLATION  OF  PARAGRAPH  FOUR  OF THIS SUBSECTION. WITH RESPECT TO EACH
 REFERENCED DRUG FOR WHICH THE SUPERINTENDENT HAS DETERMINED THE MANUFAC-
 TURER OR DISTRIBUTOR HAS FAILED TO NEGOTIATE IN GOOD FAITH, THE  PENALTY
 SHALL BE EQUAL TO:
  (A) FIVE HUNDRED THOUSAND DOLLARS; OR
  (B)  THE  AMOUNT OF ANNUAL SAVINGS DETERMINED BY THE SUPERINTENDENT AS
 DESCRIBED IN THIS SUBDIVISION, WHICHEVER IS GREATER.
 A. 9086  4
 
  ยง 2. This act shall take effect June 1, 2024.  Effective  immediately,
 the  addition,  amendment and/or repeal of any rule or regulation neces-
 sary for the implementation of  this  act  on  its  effective  date  are
 authorized to be made and completed on or before such effective date.